Kenvue Is An Interesting, High-Yield Consumer Staple

A cheap, high-yield consumer staple stock with a portfolio of recognizable brands. That’s the subject of today’s article.

Kenvue ($KVUE) is the spin-off of Johnson & Johnson’s consumer health products division. While Johnson & Johnson focuses on developing new pharmaceuticals and medical devices, Kenvue makes and markets over-the-counter products like Tylenol, Neutrogena, and Listerine.

This is a large, multibillion-dollar company. And, thanks to a rocky spin-off, Kenvue frequently offers new investors a 4%+ starting dividend yield.

But I’m getting ahead of myself…

What Does Kenvue Do?

In 2023, Johnson & Johnson spun-off their consumer health division. They named this spin-off Kenvue and gave the new company a huge portfolio of recognizable brands.

Kenvue operates in three consumer health sectors: “Self Care,” “Skin Health and Beauty,” and “Essential Health.”

“Self Care” brands include many recognizable names like Benadryl, Tylenol, and Zyrtec.

“Skin Health and Beauty” brands include Neutrogena, Aveeno, and Lubriderm.

And “Essential Health” contains household staples like Band-Aid, Listerine, and Neosporin.